Truist Financial Issues Pessimistic Forecast for Autolus Therapeutics (NASDAQ:AUTL) Stock Price

Autolus Therapeutics (NASDAQ:AUTL) had its price target cut by stock analysts at Truist Financial from $11.00 to $10.00 in a research report issued on Tuesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock.

AUTL has been the subject of several other research reports. Wells Fargo & Company decreased their price objective on Autolus Therapeutics from $8.00 to $6.00 and set an “overweight” rating for the company in a report on Friday, March 21st. Needham & Company LLC reiterated a “buy” rating and set a $10.00 target price on shares of Autolus Therapeutics in a research report on Monday, January 13th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $9.32.

Autolus Therapeutics Trading Up 11.3 %

AUTL stock opened at $1.57 on Tuesday. The stock’s fifty day simple moving average is $1.92 and its two-hundred day simple moving average is $2.77. The stock has a market cap of $417.77 million, a P/E ratio of -1.30 and a beta of 2.07. Autolus Therapeutics has a 1-year low of $1.39 and a 1-year high of $5.84.

Autolus Therapeutics (NASDAQ:AUTL) last posted its quarterly earnings data on Thursday, March 20th. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.12. The firm had revenue of $0.03 million during the quarter, compared to analysts’ expectations of $2.98 million. As a group, analysts forecast that Autolus Therapeutics will post -0.94 earnings per share for the current fiscal year.

Institutional Trading of Autolus Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Hennion & Walsh Asset Management Inc. purchased a new position in Autolus Therapeutics during the 4th quarter valued at about $611,000. Wellington Management Group LLP boosted its position in shares of Autolus Therapeutics by 35.4% in the third quarter. Wellington Management Group LLP now owns 24,220,226 shares of the company’s stock valued at $87,919,000 after acquiring an additional 6,330,392 shares during the period. FMR LLC grew its stake in Autolus Therapeutics by 44.6% during the third quarter. FMR LLC now owns 17,773,873 shares of the company’s stock valued at $64,519,000 after acquiring an additional 5,478,706 shares in the last quarter. Erste Asset Management GmbH purchased a new stake in Autolus Therapeutics in the 3rd quarter worth approximately $708,000. Finally, JPMorgan Chase & Co. boosted its holdings in Autolus Therapeutics by 145.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,284,708 shares of the company’s stock valued at $4,663,000 after purchasing an additional 761,008 shares during the period. 72.83% of the stock is currently owned by institutional investors.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.